Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: General Cardiologists (US)(?)

Council Members in this Study Group: 1333

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Howard Weintraub, MD
Clinical Director
NYU Medical Center

Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation...

Harold Bays, MD, FACP, President and Medical Director, L-MARC Research CenterHarold Bays, MD, FACP
President and Medical Director
L-MARC Research Center

Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...

Daniel Fisher, MD, FACC, FACP
Cardiologist
NYU Medical Center

Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology. He has lectured frequently on such topics as...

Joshua Feuer, MD
Owner
Joshua M. Feuer, MD

Joshua Feuer, MD, FACC, is a board certified Cardiologist in private practice in Santa Barbara, California. He also serves as a Consulting Cardiologist at Santa Barbara Cottage Hospital. Dr. Feuer specializes in aggressive preventive cardiology and cardiovascular risk assessment, and reduction. He has...

Dan Streja, MD
Clinical Professor of Medicine
University of California, Los Angeles

Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA Medical Center of West Los Angeles. Dr. Streja has...

Forrest Rubenstein, MD
Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic Surgery

Forrest Rubenstein, MD, FACS, is a Cardiac, Thoracic and Vascular Surgeon in private practice. Dr. Rubenstein is board certified in General, Cardiovascular and Thoracic Surgery. He has experience in cardiac, thoracic and vascular surgery, aortic surgery, trauma, endovascular surgery, drug eluting stents,...

Charles Glueck, MD, Medical Research Director of Cholesterol Center, Jewish HospitalCharles Glueck, MD
Medical Research Director of Cholesterol Center
Jewish Hospital

Charles Glueck, MD, is the Medical Director of Jewish Hospital Cholesterol Center in Cincinnati, Ohio. He has expertise in lipids, lipoproteins, interaction of atherosclerosis and thrombosis, thrombosis, human genetics, epidemiology, obstetrics and gynecology, and hematology. Dr Glueck and colleagues...

Bernard Chaitman, MD, Professor and Director, SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINEBernard Chaitman, MD
Professor and Director
SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE

Bernard Chaitman, MD, is a Professor of Internal Medicine and Director of Cardiovascular Research at St. Louis University School of Medicine, Missouri. He is also the Director of Core ECG Laboratory. Dr. Chaitman has research interests in anti-anginal drug therapies including Ranolazine, Nicorandil,...

View all Leading Experts in this Study Group

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
The trial that is all about hype | 08-28-2008
Author: GLG Expert Contributor

The general public hears the bullet that stents are no better than medications, but the reality that this trial (COURAGE trial) had major flaws, the main being that only 10% of the patients screened participated in the trial. 90% were excluded. Thus, the patients enrolled were not necessarily the typical...

Pancreatitis has the Potential to Kill (Byetta Sales) | 08-20-2008
Author: GLG Expert Contributor

At first, it appeared that the reports linking Byetta and pancreatitis were likely due to an association between pancreatitis and the underlying pathology in patients receiving Byetta (obesity, diabetes, gall stones, and hypertriglyceridemia). However, the additional cases of (sometimes fatal)...

PCI numbers will not drop after Courage | 08-19-2008
Author: GLG Expert Contributor

the impact will be small. The study is not a big surprise. No cardiologist thought he is saving lives stenting arteries in stable patients. The study required every one to get an angiogram if they had an abnormal stress test to qualify. We probably already not refer every abnormal test for cath using...

Bad News (but not new news) for stents. | 08-19-2008
Author: GLG Expert Contributor

Once again, we see that medications in most cases are as effective as stenting.  This is old news dating back to the CASS trial in the 1970's and 1980's. Every time we come up with a slick new device we test it against the standard of care and it comes up more expensive and no more effective. ...

Abbott Wants Seat At The Adults Table At Last! | 08-19-2008
Analysis of: Abbott signs deal to promote Crestor in U.S. | www.chicagotribune.com
Author: GLG Expert Contributor

As the market for branded statins dries up slowly now with generic simvastatin and lipitor poised for the same fate, the fixed dose combos are the only salvation for the branded drugs.  Abbott has failed to capitalize on the fact that they have the only safe effective and approved drug for raising...

View All GLG News by members of this Study Group

GLG InstituteSM Seminars with this Study Group's Leading Experts(?)

 

Recent Seminars

GLGi: Lipid Management
Boston, 03-28-2008

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Academic Institution*

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Owner
  • Physician - Division Head
  • Partner
  • Director
  • President

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-09-05T17:45:16.330